Trichosporon beigelii, an emerging pathogen resistant to amphotericin B

Thomas J. Walsh(National Cancer Institute), G. P. Melcher(National Cancer Institute), Michael G. Rinaldi(National Cancer Institute), Julius Lecciones(National Cancer Institute), D A McGough(National Cancer Institute), Paul Kelly(National Cancer Institute), J Lee(National Cancer Institute), Diana P. Callender(National Cancer Institute), Marc Rubin(National Cancer Institute), P A Pizzo(National Cancer Institute)
Journal of Clinical Microbiology
July 1, 1990
Cited by 314Open Access
Full Text

Abstract

Trichosporon beigelii caused fatal disseminated infections that were resistant to amphotericin B in two granulocytopenic patients. In vitro susceptibility studies demonstrated that both index strains of T. beigelii were inhibited but not killed by amphotericin B at achievable concentrations in serum. The minimum lethal concentration for both isolates was greater than or equal to 18 micrograms/ml. Five of seven other isolates were found to have a similar pattern of amphotericin B resistance. The fact that the minimum lethal concentration of T. beigelii was many times greater than its MIC was consistent with a resistance pattern of tolerance. We concluded that T. beigelii may be resistant in vitro to amphotericin B and that this in vitro resistance was correlated with refractory, disseminated trichosporonosis in granulocytopenic patients. T. beigelii should be included in the expanding list of amphotericin B-resistant fungi.


Related Papers